Composition, form of production and packaging
The cream for external use is 7.5% white or almost white, homogeneous.
100 g
Ribavirin 7.5 g
Auxiliary substances: glyceryl monostearate (glycerol monostearate 40-50) - 2 g, macrogol-6 cetostearyl alcohol ether (macrogol-6 cetostearyl ether) - 1.5 g, macrogol-25 cetostearyl alcohol ether (macrogol-25 cetostearyl ether) - 1.5 g, cetostearyl alcohol 5 g, liquid paraffin (vaseline oil) 5 g, methyl parahydroxybenzoate (methyl hydroxybenzoate, methylparaben, nipagin) 0.1 g, propyl parahydroxybenzoate (propyl hydroxybenzoate, propylparaben, nipazole) 0.02 g, purified water up to 100 g.
15 g - aluminum tubes (1) - cardboard packs.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2015.
PHARMACHOLOGIC EFFECT
Antiviral drug. Ribavirin triphosphate (RTF) is a potent inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase), viral RNA polymerase and viral mRNA-guanylyltransferase. Inhibition of the latter stops capping mRNA, which leads to a significant depletion of intracellular reserves of guanosine triphosphate and inhibition of the synthesis of viral RNA and protein. Ribavirin is also inserted into the viral genome, causing lethal mutations, with a subsequent decrease in the pathogenicity of the virus. Ribavirin inhibits the replication of new virions, which reduces viral load, selectively inhibits the synthesis of viral RNA, without suppressing the synthesis of RNA in normally functioning cells.
The most sensitive to ribavirin DNA viruses are herpes simplex virus, adenoviruses, CMV, smallpox viruses, Marek's diseases; RNA viruses - viruses of influenza A, B, paramyxoviruses (parainfluenza, epidemic parotitis, Nkasla disease), reoviruses, arenaviruses (Lassa fever virus, Bolivian hemorrhagic fever), bunyaviruses (Rift Valley fever virus, Crimean-Congo hemorrhagic fever virus), hantaviruses (hemorrhagic fever virus with renal or pulmonary syndrome), oncogenic RNA viruses.
Ribavirin-insensitive DNA viruses: Varicella zoster, pseudorabies virus, cowpox; RNA viruses: enteroviruses, rhinoviruses, encephalitis virus of the forest Semliki.
PHARMACOKINETICS
When applied to the skin and locally, systemic absorption is minimal and practically insignificant.
INDICATIONS
In the form of monotherapy or in combination with other medicinal forms of ribavirin for oral administration and parenteral use in the following diseases:
- infections of the skin and mucous membranes caused by Herpes simplex viruses of 1 and 2 types, of different localization, incl. in the genital area;
- Herpes zoster (as part of complex therapy).
DOSING MODE
Apply externally.
The cream is applied to the affected areas of the skin and mucous membrane (previously washed and dried) with a uniform thin layer, gently rubbing. Apply 5 times a day until the symptoms disappear completely.
In the absence of improvement within 8 days of the drug should stop taking and consult a doctor.
To obtain the best effect, treatment should be started as early as possible at the first appearance of the symptoms of the disease.
When using Derves В® cream in combination with one of the medicinal forms of ribavirin for oral or intravenous administration, the dose of the cream should be reduced.
SIDE EFFECT
Allergic reactions: possible skin rash, hives, exanthema.
Other: hair loss, change in the thyroid-stimulating hormone (TSH) content; very rarely - the symptoms of autoimmune diseases.
The observed effects, as a rule, are reversible, do not affect the effectiveness of treatment and cease after the end of treatment.
CONTRAINDICATIONS
- Pregnancy;
- the period of lactation (breastfeeding);
- children and adolescence under 18;
- Hypersensitivity to ribavirin and other components of the drug.
With caution should be used in patients with renal insufficiency, in women and men of reproductive age.
PREGNANCY AND LACTATION
The use of cream during pregnancy and during lactation is contraindicated.
Women and men of reproductive age during treatment and within 7 months after the end of therapy should use effective contraceptives.
APPLICATION FOR FUNCTIONS OF THE LIVER
Use with extreme caution in patients with renal insufficiency.
APPLICATION FOR CHILDREN
Contraindicated in the appointment of children and adolescents under 18 years
SPECIAL INSTRUCTIONS
Do not apply to the treatment of ophthalmoherpes, do not apply in the eye area.
Use with extreme caution in patients with renal insufficiency.
OVERDOSE
Data on the overdose of Dewars В® are not available.
DRUG INTERACTION
Drug interaction of the drug Devirs В® was not revealed.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children, dry place at a temperature of no higher than 25 В° C. Shelf life - 2 years.
